We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Test Identifies Positive Tuberculosis Cases Within the Hour

By LabMedica International staff writers
Posted on 27 Sep 2010
A new test can identify positive tuberculosis (TB) cases within one hour, ensuring quick treatment for patients and reducing the incidence and consequences of TB worldwide.

Researchers at the Health Protection Agency (HPA; London, United Kingdom) developed a new ultra rapid test for the TB bacteria, Mycobacterium tuberculosis, which substantially increases the sensitivity of the test, enabling detection of the presence of the bacteria in a sample within an hour. More...
The new technique is a single DNA molecule identification test, which uses real-time polymerase chain reaction (PCR).

The new test focuses on a particular DNA region within the TB bacterium, which the researchers say is present in all strains of the disease. According to the researchers, the test can pick up very small amount of bacteria, and appears to be as sensitive as the gold standard TB identification, a bacterial culture grown from mucus coughed up from the lungs. However, the standard test can take up to eight weeks to reach a diagnosis, by which time the individual might have infected many more people. The study findings were presented at the HPA's annual conference, held during September 2010 at the University of Warwick (United Kingdom).

"We're excited to have developed this new test because it means we can potentially diagnose someone at a TB clinic within an hour and start them immediately on the treatment they need,” said study author Catherine Arnold, Ph.D., head of the HPA's genomic services unit. "This new test could really have an impact where it is most needed.”

TB is a common and often deadly infectious disease that usually attacks the lungs, but can also affect other parts of the body. Most infections in humans result in an asymptomatic, latent infection, but about one in ten latent infections eventually progresses to active disease which, if left untreated, kills more than 50% of its victims. The World Health Organization (WHO, Geneva, Switzerland) has estimated that one third of the world's population carries TB bacteria, and recent years have seen resurgence in TB infections in developed countries, as well as the rise of strains resistant to medication.

Related Links:

Health Protection Agency
University of Warwick
World Health Organization


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.